Filing summary
Entity mismatch: The supplied filing is Venaxis, Inc.’s Form 10-Q for the quarter ended September 30, 2016, not a Riot Platforms, Inc. filing. The figures and disclosures below are for Venaxis and should not be attributed to Riot Platforms.
Business context and reporting period
The filing reports third-quarter and nine-month 2016 results, compared with the same periods in 2015. Venaxis was winding down its APPY 1 European commercial activities and shifting its strategy toward BiOptix Diagnostics, acquired on September 12, 2016. Venaxis acquired more than 98% of BiOptix’s voting stock for 627,010 Venaxis shares valued at approximately $2.577 million. The acquisition accounting was preliminary.
Financial performance and position
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Sales | 2016: $1,923; 2015: $57,089 | 2016: $1,923; 2015: $92,894 |
| Gross profit | 2016: $356; 2015: $42,556 | 2016: $356; 2015: $66,258 |
| Operating expenses | 2016: $1.770 million; 2015: $1.657 million | 2016: $4.069 million; 2015: $5.936 million |
| Operating loss | 2016: $1.745 million; 2015: $1.591 million | 2016: $3.996 million; 2015: $5.797 million |
| Net loss attributable to Venaxis | 2016: $1.710 million; 2015: $1.583 million | 2016: $1.986 million; 2015: $5.803 million |
| Loss per share | 2016: $0.43; 2015: $0.41 | 2016: $0.51; 2015: $1.50 |
Sales were nominal in 2016 and related to BiOptix; the filing also records license-fee revenue of $24,175 for the quarter and $72,524 year to date. Product gross margin was approximately 19% in 2016, based on the reported sales and cost of sales; license fees are reported separately. The nine-month net loss included a $1.933 million gain on the sale of property and equipment, which helped reduce the reported loss.
- At September 30, cash and cash equivalents were $2.447 million and short-term investments were $12.416 million, totaling approximately $14.863 million in cash and liquid investments. Working capital was $14.441 million.
- Total assets were $19.323 million; total liabilities were $2.268 million. Notes and other obligations were $222,135, all current; the mortgage was repaid following the property sale.
- Nine-month operating cash use was $3.841 million. Investing activities provided $4.505 million, including approximately $1.799 million from the property sale; financing activities used $229,238. Cash increased by $435,037 to $2.447 million.
- Stockholders’ equity was $17.055 million, including non-controlling interest; accumulated deficit was $107.569 million.
Changes versus the prior comparable periods
- Nine-month sales fell to $1,923 from $92,894 as APPY 1 activities were wound down. Third-quarter sales declined to $1,923 from $57,089.
- Nine-month operating expenses declined by approximately $1.867 million, primarily as APPY development and commercialization were reduced. The third-quarter operating loss nevertheless increased, with higher SG&A—including accrued incentives, BiOptix costs, and acquisition-related legal costs—more than offsetting lower R&D.
- Nine-month net loss improved substantially from 2015, principally reflecting lower operating expenses and the one-time property-sale gain. Excluding that gain, the filing does not present a comparable adjusted loss measure.
- Cash from operations improved from $5.216 million used in the first nine months of 2015 to $3.841 million used in 2016.
Outlook, risks, contingencies, and unusual items
- Management expected continued near-term operating losses, potentially increasing with BiOptix-related costs, and said existing working capital was expected to fund estimated cash needs into 2017. The company was monitoring spending and might seek additional financing; there was no assurance financing would be available on acceptable terms.
- Management planned to develop BiOptix, pursue partnering or licensing opportunities, explore monetization or partnering of its appendicitis portfolio, and control costs. No specific revenue or earnings guidance was provided.
- Management warned that approximately $335,000 of capitalized appendicitis patent costs could be impaired if no strategic partner or other interested party were found. The filing also reports $200,000 of net patent impairment charges for the first nine months of 2016.
- The BiOptix purchase-price allocation was preliminary. Acquired intangible assets were estimated to require approximately $460,000 of annual amortization over estimated lives of four to six years.
- The February 2016 headquarters sale generated approximately $1.7 million net cash after expenses and mortgage payoffs and a gain of approximately $1.9 million. The company continued to lease back storage space short term.
- Venaxis had resolved a dispute with two former European distributors in August 2016; settlement terms were confidential. It reported no legal proceeding expected by management to have a material adverse effect.
- Risks included the early-stage nature of BiOptix commercialization, competition, manufacturing and margin challenges, possible need for further capital and shareholder dilution, and potential shareholder efforts to effect a change in control. The company also disclosed that approximately 18% shareholders had sought a special meeting and indicated intent to pursue change-of-control action.
Important facts to verify
- Confirm that Venaxis—not Riot Platforms—is the intended issuer and that the filing period is 2016 Q3.
- Review the completed BiOptix purchase-price allocation, subsequent commercialization progress, and actual revenue and margins against management’s plans.
- Track operating cash use, liquid investments, financing needs, and whether management’s estimate of funding into 2017 was achieved.
- Assess the recoverability of appendicitis patent assets and any additional impairment charges.
- Review subsequent filings for developments in shareholder matters, strategic alternatives, and any material contingent or contractual obligations.